Eva Kimby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eva Kimby has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Asgerdur Sverrisdottir
1 shared publicationGöran Elinder
1 shared publication
Latest Publications
- 1 December 2012
- Vol. 34 (4) , 384-5
Leukemic phase of B-lineage NHL.
- 8 March 2004
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4) , 292-295
Safety of rituximab therapy during the first trimester of pregnancy: a case history
The optimal treatment of non‐Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.
- 8 March 2004
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4) , 292-295
Safety of rituximab therapy during the first trimester of pregnancy: a case history
The optimal treatment of non‐Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.